Cargando…

Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells

[Image: see text] We recently demonstrated the far-red light-activatable prodrug of paclitaxel (PTX), Pc-(L-PTX)(2). Upon illumination with a 690 nm laser, Pc-(L-PTX)(2) showed combinational cell killing from rapid photodynamic therapy damage by singlet oxygen, followed by sustained chemotherapy eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Thapa, Pritam, Li, Mengjie, Karki, Radha, Bio, Moses, Rajaputra, Pallavi, Nkepang, Gregory, Woo, Sukyung, You, Youngjae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664141/
https://www.ncbi.nlm.nih.gov/pubmed/29104951
http://dx.doi.org/10.1021/acsomega.7b01105
_version_ 1783274948205215744
author Thapa, Pritam
Li, Mengjie
Karki, Radha
Bio, Moses
Rajaputra, Pallavi
Nkepang, Gregory
Woo, Sukyung
You, Youngjae
author_facet Thapa, Pritam
Li, Mengjie
Karki, Radha
Bio, Moses
Rajaputra, Pallavi
Nkepang, Gregory
Woo, Sukyung
You, Youngjae
author_sort Thapa, Pritam
collection PubMed
description [Image: see text] We recently demonstrated the far-red light-activatable prodrug of paclitaxel (PTX), Pc-(L-PTX)(2). Upon illumination with a 690 nm laser, Pc-(L-PTX)(2) showed combinational cell killing from rapid photodynamic therapy damage by singlet oxygen, followed by sustained chemotherapy effects from locally released PTX. However, its high lipophilicity (log D(7.4) > 3.1) caused aggregation in aqueous solutions and has nonselectivity toward cancer cells. To solve these important problems, we prepared folic acid (FA)-conjugated and photoactivatable prodrugs of PTX with a polyethylene glycol (PEG) spacer of various chain lengths: FA-PEG(n)-Pc-L-PTX [n = 0 (0k, 5), ∼23 (1k, 7a), ∼45 (2k, 7b), ∼80 (3.5k, 7c), or ∼114 (5k, 7d)]. The PEGylated prodrugs 7a–d had a much improved hydrophilicity compared with the non-PEGylated prodrug, Pc-(L-PTX)(2). As the PEG length increased, the hydrophilicity of the prodrug increased (log D(7.4) values: 1.28, 0.09, −0.24, and −0.59 for 1k, 2k, 3.5k, and 5k PEG prodrugs, respectively). Fluorescence spectral data suggested that the PEGylated prodrugs had good solubility in the culture medium at lower concentrations (<1–2 μM), but showed fluorescence quenching due to limited solubility at higher concentrations (>2 μM). Dynamic light scattering indicated that all of the prodrugs formed nanosized particles in both phosphate-buffered saline and culture medium at a concentration of 5 μM. The PEG length affected both nonspecific and folate receptor (FR)-mediated uptake of the prodrugs. The enhanced cellular uptake was observed for the prodrugs with medium-sized PEGs (1k, 2k, or 3.5k) in FR-positive SKOV-3 cells, but not for the prodrugs with no PEG or with the longest PEG (5k), which suggests the optimal range of PEG length around 1k–3.5k for effective uptake of our prodrug system. Consistent with the cellular uptake pattern, medium-sized PEGylated prodrugs showed more potent phototoxic activity (IC(50s), ∼130 nM) than prodrugs with no PEG or the longest PEG (IC(50), ∼400 nM). In conclusion, we have developed far-red light-activatable prodrugs with improved water solubility and FR-targeting properties compared with the nontargeted prodrug.
format Online
Article
Text
id pubmed-5664141
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-56641412017-11-02 Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells Thapa, Pritam Li, Mengjie Karki, Radha Bio, Moses Rajaputra, Pallavi Nkepang, Gregory Woo, Sukyung You, Youngjae ACS Omega [Image: see text] We recently demonstrated the far-red light-activatable prodrug of paclitaxel (PTX), Pc-(L-PTX)(2). Upon illumination with a 690 nm laser, Pc-(L-PTX)(2) showed combinational cell killing from rapid photodynamic therapy damage by singlet oxygen, followed by sustained chemotherapy effects from locally released PTX. However, its high lipophilicity (log D(7.4) > 3.1) caused aggregation in aqueous solutions and has nonselectivity toward cancer cells. To solve these important problems, we prepared folic acid (FA)-conjugated and photoactivatable prodrugs of PTX with a polyethylene glycol (PEG) spacer of various chain lengths: FA-PEG(n)-Pc-L-PTX [n = 0 (0k, 5), ∼23 (1k, 7a), ∼45 (2k, 7b), ∼80 (3.5k, 7c), or ∼114 (5k, 7d)]. The PEGylated prodrugs 7a–d had a much improved hydrophilicity compared with the non-PEGylated prodrug, Pc-(L-PTX)(2). As the PEG length increased, the hydrophilicity of the prodrug increased (log D(7.4) values: 1.28, 0.09, −0.24, and −0.59 for 1k, 2k, 3.5k, and 5k PEG prodrugs, respectively). Fluorescence spectral data suggested that the PEGylated prodrugs had good solubility in the culture medium at lower concentrations (<1–2 μM), but showed fluorescence quenching due to limited solubility at higher concentrations (>2 μM). Dynamic light scattering indicated that all of the prodrugs formed nanosized particles in both phosphate-buffered saline and culture medium at a concentration of 5 μM. The PEG length affected both nonspecific and folate receptor (FR)-mediated uptake of the prodrugs. The enhanced cellular uptake was observed for the prodrugs with medium-sized PEGs (1k, 2k, or 3.5k) in FR-positive SKOV-3 cells, but not for the prodrugs with no PEG or with the longest PEG (5k), which suggests the optimal range of PEG length around 1k–3.5k for effective uptake of our prodrug system. Consistent with the cellular uptake pattern, medium-sized PEGylated prodrugs showed more potent phototoxic activity (IC(50s), ∼130 nM) than prodrugs with no PEG or the longest PEG (IC(50), ∼400 nM). In conclusion, we have developed far-red light-activatable prodrugs with improved water solubility and FR-targeting properties compared with the nontargeted prodrug. American Chemical Society 2017-10-04 /pmc/articles/PMC5664141/ /pubmed/29104951 http://dx.doi.org/10.1021/acsomega.7b01105 Text en Copyright © 2017 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Thapa, Pritam
Li, Mengjie
Karki, Radha
Bio, Moses
Rajaputra, Pallavi
Nkepang, Gregory
Woo, Sukyung
You, Youngjae
Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells
title Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells
title_full Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells
title_fullStr Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells
title_full_unstemmed Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells
title_short Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells
title_sort folate-peg conjugates of a far-red light-activatable paclitaxel prodrug to improve selectivity toward folate receptor-positive cancer cells
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664141/
https://www.ncbi.nlm.nih.gov/pubmed/29104951
http://dx.doi.org/10.1021/acsomega.7b01105
work_keys_str_mv AT thapapritam folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells
AT limengjie folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells
AT karkiradha folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells
AT biomoses folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells
AT rajaputrapallavi folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells
AT nkepanggregory folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells
AT woosukyung folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells
AT youyoungjae folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells